| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| Other Sizes |
| Targets |
Triphenylphosphinechlorogold targets apoptosis induction in cancer cells. Its mechanism of action involves significant lipoxygenase (LOX) inhibitory activity, leading to cell cycle arrest and apoptosis. A weak interaction with DNA may be involved in its mechanism of action. The compound induces apoptosis through mechanisms that differ from traditional chemotherapeutics like cisplatin. It also acts as a catalyst in various biochemical reactions.
|
|---|---|
| ln Vitro |
In vitro, triphenylphosphinechlorogold demonstrates significant lipoxygenase (LOX) inhibitory activity. It shows antiproliferative effects against breast cancer cell lines. The compound has been investigated for its antiproliferative activity against human breast adenocarcinoma cells, and it has been confirmed that the complex has no in vitro toxicity against normal human fetal lung fibroblast cells. It induces apoptosis in cancer cells.
|
| ln Vivo |
In vivo data for triphenylphosphinechlorogold are limited. The compound has been studied for its anticancer activity, but specific in vivo pharmacokinetic and pharmacodynamic data are not well-documented. As a gold(I) complex, it may have potential for in vivo applications in cancer therapy, but further studies are needed. The compound's in vivo relevance is primarily through its antiproliferative and apoptotic effects observed in vitro.
|
| Enzyme Assay |
For in vitro enzyme inhibition assays, triphenylphosphinechlorogold is evaluated for lipoxygenase (LOX) inhibitory activity. Enzyme activity is measured spectrophotometrically using linoleic acid as substrate. The compound (0.01-100 µM) is pre-incubated with the enzyme for 5-10 minutes at 25°C before substrate addition. IC₅₀ values are calculated from dose-response curves. The compound demonstrates significant LOX inhibitory activity.
|
| Cell Assay |
For in vitro cell-based experiments, triphenylphosphinechlorogold is evaluated for antiproliferative and apoptotic activity against cancer cell lines such as breast adenocarcinoma cells. Cells are seeded in 96-well plates and treated with the compound at various concentrations (typically 0.1-100 µM) for 24-72 hours. Cell viability is assessed using MTT or resazurin-based assays. Apoptosis is measured using flow cytometry with Annexin V/PI staining.
|
| Animal Protocol |
In vivo animal studies for triphenylphosphinechlorogold are limited. For anticancer drug candidates derived from this compound, efficacy studies would typically be performed in mouse xenograft models of cancer. Standard in vivo protocols involve administration to tumor-bearing mice via intravenous or intraperitoneal injection, with measurement of tumor volume over time. Specific protocols for this compound are not well-documented in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of triphenylphosphinechlorogold are not extensively characterized. The compound has a molecular weight of 494.71 g/mol. As a gold(I) complex with a lipophilic triphenylphosphine ligand, it is expected to have moderate lipophilicity and potential for membrane permeability. The compound's gold center may interact with thiol-containing biomolecules. Empirical pharmacokinetic data (half-life, clearance, bioavailability) are not available in the public literature.
|
| Toxicity/Toxicokinetics |
Triphenylphosphinechlorogold is a research chemical and should be handled with appropriate laboratory safety precautions. As a gold complex, it may cause skin and eye irritation. The compound should be stored under appropriate conditions. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment and working in a fume hood.
|
| Additional Infomation |
Triphenylphosphinechlorogold (Chloro(triphenylphosphine)gold(I), CAS 14243-64-2) is primarily a research-grade chemical, not an FDA-approved pharmaceutical drug. Its primary applications are in cancer research as an apoptotic agent. The compound demonstrates significant lipoxygenase inhibitory activity and antiproliferative effects against cancer cell lines. It induces apoptosis through mechanisms that differ from traditional chemotherapeutics. No clinical trials or approved indications exist for this compound.
|
| Molecular Formula |
C18H15AUCLP
|
|---|---|
| Molecular Weight |
494.71
|
| Exact Mass |
494.026
|
| CAS # |
14243-64-2
|
| PubChem CID |
10874691
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
360ºC at 760 mmHg
|
| Melting Point |
248-249°C
|
| Flash Point |
181.7ºC
|
| Vapour Pressure |
4.74E-05mmHg at 25°C
|
| LogP |
4.131
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
0
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
204
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Au]Cl.P(C1C([H])=C([H])C([H])=C([H])C=1[H])(C1C([H])=C([H])C([H])=C([H])C=1[H])C1C([H])=C([H])C([H])=C([H])C=1[H]
|
| InChi Key |
IFPWCRBNZXUWGC-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C18H15P.Au.ClH/c1-4-10-16(11-5-1)19(17-12-6-2-7-13-17)18-14-8-3-9-15-18;;/h1-15H;;1H/q;+1;/p-1
|
| Chemical Name |
chlorogold;triphenylphosphane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0214 mL | 10.1069 mL | 20.2139 mL | |
| 5 mM | 0.4043 mL | 2.0214 mL | 4.0428 mL | |
| 10 mM | 0.2021 mL | 1.0107 mL | 2.0214 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
